X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Fortress expects to use the net proceeds for its operations, including, research and development and clinical trial expenditures of its pipeline, including CK-301 (cosibelimaba) fully-human monoclonal antibody of IgG1 subtype.
Lead Product(s): Cosibelimab,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 03, 2024
Details:
Fortress expects to use the net proceeds for its operations, including, research and development and clinical trial expenditures of its pipeline, including Cosibelimaba fully-human monoclonal antibody of IgG1 subtype,
Lead Product(s): Cosibelimab,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 29, 2023
Details:
The net proceeds will be used for the development of CK-301 (cosibelimab), an investigational fully-human monoclonal antibody that binds programmed death-ligand 1 and blocks its interaction with Programmed cell death protein 1.
Lead Product(s): Cosibelimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 14, 2023
Details:
The net proceeds will be used for the development of CK-301 (cosibelimab), an investigational fully-human monoclonal antibody that binds programmed death-ligand 1 and blocks its interaction with Programmed cell death protein 1.
Lead Product(s): Cosibelimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 10, 2023
Details:
Under the agreement, Helocyte gains patent rights to use CMV-MVA Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus-specific, Anti-HIV CAR T Cells for the treatment of adults living with HIV.
Lead Product(s): CMV-MVA Triplex
Therapeutic Area: Infections and Infectious Diseases Product Name: CMV-MVA Triplex
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: City of Hope
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 16, 2023
Details:
Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Lead Product(s): Dotinurad
Therapeutic Area: Rheumatology Product Name: Urece
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Urica Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
The funding will be used for clinical studies of Triplex, a cytomegalovirus (CMV), universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara viral vector vaccine, being developed by Helocyte and City of Hope.
Lead Product(s): CMV-MVA Triplex Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Triplex
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Funding June 15, 2023
Details:
BAER-101 is a high affinity, selective modulator of the GABA A receptor system, with differential binding and modulatory properties dependent on the particular GABA A subtype.
Lead Product(s): BAER-101
Therapeutic Area: Psychiatry/Psychology Product Name: BAER-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avenue Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 08, 2022
Details:
Triplex is a universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara viral vector vaccine engineered to induce a robust and durable CMV-specific T cell response to three immuno-dominant proteins.
Lead Product(s): CMV-modified Vaccinia Ankara Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Triplex
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 11, 2022
Details:
Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia. Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials.
Lead Product(s): Dotinurad
Therapeutic Area: Rheumatology Product Name: Urece
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fuji Yakuhin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
